Plecanatide

Source high-purity Plecanatide, a synthetic guanylate cyclase-C (GC-C) agonist peptide designed for advanced gastrointestinal research. This 16-amino acid peptide mimics endogenous uroguanylin, offering exceptional stability in acidic environments and potent regulatory effects on intestinal fluid secretion. Ideal for laboratories investigating IBS-C mechanisms, chronic constipation pathways, and epithelial transport physiology. High-quality raw material. Get a quote today!

Product Specification

• Product Name: Plecanatide (Research Grade)
• Appearance: White to off-white lyophilized powder
• CAS No.: 1082732-96-4
• Molecular Formula: C₇₀H₁₀₄N₂₀O₂₆S₆
• Specification: Purity ≥98% (HPLC); Molecular Weight: ~1679.8 g/mol; Sequence: Ac-Cys-Cys-Glu-Tyr-Asp-Cys-Cys-Val-Asn-Tyr-Ala-Cys-Thr-Gly-Cys-Cys-NH₂ (with 3 disulfide bonds)
• Ingredient Information: Synthetic peptide analog of uroguanylin; Stabilized against acid degradation; Endotoxin <1.0 EU/mg

Product Description

Plecanatide is a sophisticated synthetic peptide that acts as a selective agonist of the guanylate cyclase-C (GC-C) receptor located on the luminal surface of the intestinal epithelium. Structurally similar to endogenous uroguanylin, it features three disulfide bonds that confer remarkable stability in the acidic environment of the stomach, ensuring efficient delivery to the small intestine. Upon binding to GC-C, it triggers an intracellular cascade increasing cyclic GMP (cGMP), which regulates chloride and bicarbonate secretion into the intestinal lumen. This mechanism accelerates intestinal transit and softens stool consistency without systemic absorption. In research settings, Plecanatide is valued for its high specificity and potency, making it a critical tool for studying fluid homeostasis, visceral pain modulation, and the pathophysiology of functional gastrointestinal disorders.

Product Uses

This ingredient is strictly intended for laboratory research and preclinical studies. It is widely used in gastrointestinal physiology research to investigate the role of GC-C signaling in intestinal fluid and electrolyte transport. Scientists utilize Plecanatide in animal models of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) to evaluate therapeutic efficacy and mechanism of action. Additionally, it serves as a key reagent in cell-based assays using intestinal epithelial cell lines to study cGMP pathway activation, tight junction integrity, and visceral hypersensitivity. It is not approved for human consumption or clinical use outside of regulated trials.

Formulation Recommendation

Reconstitution: Dissolve in sterile deionized water or PBS containing 0.1% BSA to prevent adsorption to container walls. Gentle vortexing is recommended. Prepare stock solutions at 1–5 mg/mL. Aliquot and store at -80°C.
Usage Concentration: In vitro, typical concentrations range from 1 nM to 100 nM for cell culture assays measuring cGMP production or ion transport. In vivo, dosing in mouse/rat models often ranges from 0.1–10 mg/kg via oral gavage, depending on the study design.
Compatibility: Stable in acidic conditions (pH 1–3) simulating gastric environment. Compatible with standard physiological buffers. Avoid repeated freeze-thaw cycles. For oral administration studies, ensure formulation protects peptide integrity until intestinal release if not relying on its inherent acid stability.